GALE 301 / SELLAS Life Sciences - LARVOL DELTA

Galena Biopharma to present GALE-301 phase 2a clinical trial data at the European Society for Medical Oncology (ESMO) European Cancer Congress 2015 (Market Watch) - "Galena Biopharma...today announced that data from the Company's Phase 2a portion of the Phase 1/2a clinical trial of GALE-301, or Folate Binding Protein, will be presented at the upcoming European Society for Medical Oncology (ESMO)...Abstract #:2764. Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients."

Anticipated P2 data • Ovarian Cancer